Mucormycosis and aspergillosis: The deadly duo in COVID-19—a case report

Autor: Bijaya Mohanty, Zeya Ansari, Anil Prasad, Minakshi Gupta, Alok Kumar

Publikováno v: Journal of Family Medicine and Primary Care, Vol 11, Iss 10, Pp 6529-6532 (2022)

COVID-19 disease has been associated with fungal infections such as aspergillosis and mucormycosis, especially in diabetic patients who have suffered from a moderately severe form of COVID-19 infection and are treated with steroids. Though there are

Externí odkaz: https://doaj.org/article/ae439f55e5cb43aa98a3e1efbc2f0551

Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells

Autor: Mohammad Salik Zeya Ansari, Venturina Stagni, Angela Iuzzolino, Dante Rotili, Antonello Mai, Donatella Del Bufalo, Patrizia Lavia, Francesca Degrassi, Daniela Trisciuoglio

Publikováno v: Cancer Gene Therapy. 30:124-136

p300/CBP histone acetyltransferases (HAT) are critical transcription coactivators involved in multiple cellular activities. They act at multiple levels in non-small cell lung carcinoma (NSCLC) and appear, therefore, as promising druggable targets. He

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02aaf8e18edd2047e2fcfdabf1a099f6
https://doi.org/10.1038/s41417-022-00524-8

Front Cover: Chemically Diverse S. mansoni HDAC8 Inhibitors Reduce Viability in Worm Larval and Adult Stages (ChemMedChem 3/2023)

Autor: Beatrice Noce, Elisabetta Di Bello, Clemens Zwergel, Rossella Fioravanti, Sergio Valente, Dante Rotili, Andrea Masotti, Mohammad Salik Zeya Ansari, Daniela Trisciuoglio, Alokta Chakrabarti, Christophe Romier, Dina Robaa, Wolfgang Sippl, Manfred Jung, Cécile Häberli, Jennifer Keiser, Antonello Mai

Publikováno v: ChemMedChem. 18

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2c630a134388125c82bf2e083676802
https://doi.org/10.1002/cmdc.202300028

First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53

Autor: Eline Hendrix, Anthony Tumber, Klemensas Simelis, Mathew L. Coleman, Nicola Mautone, Akane Kawamura, Catrine Johansson, Alessia Ciogli, Udo Oppermann, Dante Rotili, Lorenzo Antonini, Manuela Sabatino, Daniela Passeri, Antonello Mai, Mohammad Salik Zeya Ansari, Regina Andrijes, Daniela Trisciuoglio, Eidarus Salah, Donatella Del Bufalo, Francesca Romana Pellegrini, Radosław P Nowak, Roberto Pellicciari, Rino Ragno, Christopher J. Schofield

Publikováno v: Journal of Medicinal Chemistry
Journal of medicinal chemistry 64 (2021): 17031–17050. doi:10.1021/acs.jmedchem.1c00605
info:cnr-pdr/source/autori:Nowak R.P.; Tumber A.; Hendrix E.; Ansari M.S.Z.; Sabatino M.; Antonini L.; Andrijes R.; Salah E.; Mautone N.; Pellegrini F.R.; Simelis K.; Kawamura A.; Johansson C.; Passeri D.; Pellicciari R.; Ciogli A.; Del Bufalo D.; Ragno R.; Coleman M.L.; Trisciuoglio D.; Mai A.; Oppermann U.; Schofield C.J.; Rotili D./titolo:First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53/doi:10.1021%2Facs.jmedchem.1c00605/rivista:Journal of medicinal chemistry/anno:2021/pagina_da:17031/pagina_a:17050/intervallo_pagine:17031–17050/volume:64

MINA53 is a JmjC domain 2-oxoglutarate-dependent oxygenase that catalyzes ribosomal hydroxylation and is a target of the oncogenic transcription factor c-MYC. Despite its anticancer target potential, no small-molecule MINA53 inhibitors are reported.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7a2018a4fda17782bb28cfc487a6ff
https://doi.org/10.1021/acs.jmedchem.1c00605

Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models

Autor: Martina Menna, Francesco Fiorentino, Biagina Marrocco, Alessia Lucidi, Stefano Tomassi, Domenica Cilli, Mauro Romanenghi, Matteo Cassandri, Silvia Pomella, Michele Pezzella, Donatella Del Bufalo, Mohammad Salik Zeya Ansari, Nevena Tomašević, Milan Mladenović, Monica Viviano, Gianluca Sbardella, Rossella Rota, Daniela Trisciuoglio, Saverio Minucci, Andrea Mattevi, Dante Rotili, Antonello Mai

LSD1 is a histone lysine demethylase proposed as therapeutic target in cancer. Chemical modifications applied at C2, C4 and/or C7 positions of the quinazoline core of the previously reported dual LSD1/G9a inhibitor 1 led to a series of non-covalent,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174de47d6b2349a453af568efe1b2572
http://hdl.handle.net/11588/895173